4//SEC Filing
Wyskiel Christina W 4
Accession 0000947871-09-000141
CIK 0001222929other
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 4:30 PM ET
Size
11.1 KB
Accession
0000947871-09-000141
Insider Transaction Report
Form 4
Wyskiel Christina W
Director
Transactions
- Disposition from Tender
Stock Options
2009-02-25−23,319→ 0 totalExercise: $7.36From: 2007-11-13Exp: 2017-11-12→ Common Stock (23,319 underlying) - Disposition from Tender
Stock Options
2009-02-25−6,681→ 0 totalExercise: $5.11From: 2007-10-09Exp: 2017-10-08→ Common Stock (6,681 underlying) - Disposition from Tender
Stock Options
2009-02-25−40,000→ 0 totalExercise: $5.71Exp: 2011-08-14→ Common Stock (40,000 underlying)
Footnotes (5)
- [F1]These Stock Options are held by Christina Wyskiel for the benefit of Maverick Fund, L.D.C., Maverick Fund USA, Ltd., and Maverick Fund II, Ltd. Ms. Wyskiel is an employee of an affiliate of Maverick Capital Ltd.
- [F2]These Stock Options are exercisable in three equal annual installments. The first installment became exercisable on August 15, 2007, the second installment became exercisable on August 15, 2008, and the third installment will become exercisable on August 15, 2009.
- [F3]Pursuant to the merger agreement between Replidyne, Inc., Responder Merger Sub, Inc. and the issuer, dated November 3, 2008, (the "Merger Agreement"), these Stock Options were assumed on 02/25/2009 by Replidyne, Inc. and replaced with options to purchase 15,087 shares of Replidyne, Inc. common stock at an exercise price of $11.38 and otherwise having the same terms and conditions as the assumed Stock Options.
- [F4]Pursuant to the Merger Agreement, these Stock Options were assumed on 02/25/2009 by Replidyne, Inc. and replaced with a stock option to purchase 4,322 shares of Replidyne, Inc. common stock at an exercise price of $7.90 and otherwise having the same terms and conditions as the assumed Stock Options.
- [F5]Pursuant to the Merger Agreement, these Stock Options were assumed on 02/25/2009 by Replidyne, Inc. and replaced with a stock option to purchase 25,880 shares of Replidyne, Inc. common stock at an exercise price of $8.83 and otherwise having the same terms and conditions as the assumed Stock Options.
Documents
Issuer
CARDIOVASCULAR SYSTEMS INC
CIK 0001222929
Entity typeother
Related Parties
1- filerCIK 0001428727
Filing Metadata
- Form type
- 4
- Filed
- Feb 26, 7:00 PM ET
- Accepted
- Feb 27, 4:30 PM ET
- Size
- 11.1 KB